151 related articles for article (PubMed ID: 25659373)
21. Distribution and clinical significance of circulating CD8
Yu X; Lin Y; Chen H; Wu MJ; Huang LN; Song YY; Gu BB; Ye ZJ; Xu P; Zhang JP; Xu JC
BMC Pulm Med; 2022 Jul; 22(1):291. PubMed ID: 35907816
[TBL] [Abstract][Full Text] [Related]
22. Defective response of CD4(+) T cells to retinoic acid and TGFβ in systemic lupus erythematosus.
Sobel ES; Brusko TM; Butfiloski EJ; Hou W; Li S; Cuda CM; Abid AN; Reeves WH; Morel L
Arthritis Res Ther; 2011 Jun; 13(3):R106. PubMed ID: 21708033
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
Gridelli C; Gallo C; Shepherd FA; Illiano A; Piantedosi F; Robbiati SF; Manzione L; Barbera S; Frontini L; Veltri E; Findlay B; Cigolari S; Myers R; Ianniello GP; Gebbia V; Gasparini G; Fava S; Hirsh V; Bezjak A; Seymour L; Perrone F
J Clin Oncol; 2003 Aug; 21(16):3025-34. PubMed ID: 12837810
[TBL] [Abstract][Full Text] [Related]
24. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma.
Meloni F; Morosini M; Solari N; Passadore I; Nascimbene C; Novo M; Ferrari M; Cosentino M; Marino F; Pozzi E; Fietta AM
Hum Immunol; 2006; 67(1-2):1-12. PubMed ID: 16698419
[TBL] [Abstract][Full Text] [Related]
25. First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.
Li Y; Wang LR; Chen J; Lou Y; Zhang GB
Dis Markers; 2014; 2014():960458. PubMed ID: 24591771
[TBL] [Abstract][Full Text] [Related]
26. Age-related changes in CD4+CD25+FOXP3+ regulatory T cells and their relationship with lung cancer.
Hou PF; Zhu LJ; Chen XY; Qiu ZQ
PLoS One; 2017; 12(3):e0173048. PubMed ID: 28253320
[TBL] [Abstract][Full Text] [Related]
27. Increased frequency and FOXP3 expression of human CD8
Zahran AM; Nafady-Hego H; Mansor SG; Abbas WA; Abdel-Malek MO; Mekky MA; Hetta HF
Hum Immunol; 2019 Jul; 80(7):510-516. PubMed ID: 30904437
[TBL] [Abstract][Full Text] [Related]
28. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
[TBL] [Abstract][Full Text] [Related]
29. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
30. Decreased suppression of CD8
Giri PS; Dwivedi M; Begum R
Exp Dermatol; 2020 Aug; 29(8):759-775. PubMed ID: 32682346
[TBL] [Abstract][Full Text] [Related]
31. [Changes of regulatory T cells in the peripheral blood of children with epilepsy].
Li C; Ma WN; Wang H
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Nov; 13(11):889-92. PubMed ID: 22099198
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.
Cappuzzo F; Selvaggi G; Gregorc V; Mazzoni F; Betti M; Rita Migliorino M; Novello S; Maestri A; De Marinis F; Darwish S; De Angelis V; Nelli F; Bartolini S; Scagliotti GV; Tonato M; Crinò L
Cancer; 2003 Jul; 98(1):128-34. PubMed ID: 12833465
[TBL] [Abstract][Full Text] [Related]
33. The variation of CD4+CD25+ regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN.
Wang YY; He XY; Cai YY; Wang ZJ; Lu SH
Target Oncol; 2011 Sep; 6(3):147-54. PubMed ID: 21611754
[TBL] [Abstract][Full Text] [Related]
34. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer.
Okita R; Saeki T; Takashima S; Yamaguchi Y; Toge T
Oncol Rep; 2005 Nov; 14(5):1269-73. PubMed ID: 16211295
[TBL] [Abstract][Full Text] [Related]
35. Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model.
Wu L; Yun Z; Tagawa T; Rey-McIntyre K; Anraku M; de Perrot M
J Thorac Oncol; 2011 Sep; 6(9):1578-86. PubMed ID: 21642867
[TBL] [Abstract][Full Text] [Related]
36. Dose escalation of gemcitabine concomitant with radiation and cisplatin for nonsmall cell lung cancer: a phase 1-2 study.
Momm F; Kaden M; Tannock I; Schumacher M; Hasse J; Henke M
Cancer; 2010 Oct; 116(20):4833-9. PubMed ID: 20589760
[TBL] [Abstract][Full Text] [Related]
37. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Alberola V; Camps C; Provencio M; Isla D; Rosell R; Vadell C; Bover I; Ruiz-Casado A; Azagra P; Jiménez U; González-Larriba JL; Diz P; Cardenal F; Artal A; Carrato A; Morales S; Sanchez JJ; de las Peñas R; Felip E; López-Vivanco G;
J Clin Oncol; 2003 Sep; 21(17):3207-13. PubMed ID: 12947054
[TBL] [Abstract][Full Text] [Related]
39. CD13+CD4+CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients.
Ju S; Qiu H; Zhou X; Zhu B; Lv X; Huang X; Li J; Zhang Y; Liu L; Ge Y; Johnson DE; Ju S; Shu Y
Cell Cycle; 2009 Aug; 8(16):2578-85. PubMed ID: 19597336
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
Han JY; Lee DH; Song JE; Lee SY; Kim HY; Kim HT; Lee JS
Cancer; 2008 Jul; 113(2):388-95. PubMed ID: 18484595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
